Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Общие и местные факторы риска нейропатической боли при синдроме карпального канала
Общие и местные факторы риска нейропатической боли при синдроме карпального канала
Пизова Н.В., Дружинин Д.С. Общие и местные факторы риска нейропатической боли при синдроме карпального канала. Consilium Medicum. 2014; 16 (9): 41–44.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Аль-Замиль М.Х. Карпальный синдром. Клин. неврология. 2008; 1: 41–5.
2. Левин О.С. Полинейропатии. М.: МИА, 2005.
3. Johnson EW. Practical Electromyography. Baltimore: Williams and Wilkins, 1980; p. 101, 180, 230.
4. Johnson EW, Kraft GW. Carpal Tunnel Syndrome. Phys Med Rehab Clin N Am 1997; 8: 3.
5. Klippel JH. Primer on the Rheumatic Disease. 12th Ed. Atlanta: Arthritis Foundation, 2001; p. 180.
6. Кипервас И.П. Туннельные синдромы. Изд. 3-е. М.: Ньюдиамед, 2010.
7. Жулев Н.М. Невропатии: руководство для врачей. СПб.: СпБмапо, 2005.
8. Bland JD. Carpal tunnel syndrome. BMJ 2007; 335 (7615): 343–6.
9. Lishman WA, Russel WR. The brachial Neuropathies. Lancet 1961; 2: 941–7.
10. Commesson C et al. Chronic upper extremity pain and co-occurring symptoms in a general population. Arthritis Rheum 2003; 49 (5): 697–702.
11. De Krommc, Kester AD, Knipschild PG et al. Risk factors for carpal tunnel syndrome. Am J Epidemiol 1990; 132 (6): 1102–10.
12. Smith HS, Sang CN. The evolving nature of neuropathic pain: individualizing treatment. Eur J Pain 2002; 6 (Suppl. B): 13–8.
13. Данилов А.Б., Давыдов О.С. Диагностические шкалы для оценки нейропатической боли. Боль. 2007; 3 (16): 11–5.
14. Берзиньш Ю.Э., Думбере Р.Т. Туннельные поражения нервов верхней конечности. Рига: Зинатне, 1989.
15. Данилов А.Б. Габапентин (Нейронтин) в лечении нейропатической боли. Клин. фармакология и терапия. 2004; 13: 4.
16. Wesche D, Bockbrader H. A pharmacokinetic comparison of pregabalin and gabapentin; http://www.ampainsoc.org/abstract/2005/data/684/index.html
17. Levien TL. Summary of new drug applications and biologic license applications submitted to the Food and Drug Administration: Pregabalin-Pfizer. Advances in Pharmacy 2004; 2 (2): 185–6.
18. Taylor CP. The Biology and Pharmacology of Calcium Channel a2-delta Proteins. Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA. CNS Drug Reviews 2003; 10 (2): 183–8.
19. Freynhagen R, Strogek K, GriesingT et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicenter placebo-controlled trial of fexible- and fixed-dose regimen. Pain 2005; 115 (30): 254–63.
20. Siddall PJ, Cousins MJ, Otte A et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67 (10): 1792–800.
21. Vranken JH et al. Pregabalin in patients with central neuropathic pain:
A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2007.
22. Lesser H, Sharma U, La Moreaux L et al. Pregabalin relieves symptoms of painful diabetic europathy randomized control trial. Neurology 2004; 63 (11): 2104–10.
23. Ritcher RW, Portenoy R, Sharma U et al. Relief of painful diabetic neuropathy with pregabalin: a randomized, placebo-controlled trial. Pain 2005; 6 (4): 235–60.
24. Rosenstock J, Truchman M, La Moreaux. Pregabalin feo the gratment of painful diabetic periphera; l neuropathy. A double-blind placebo-controlled trial. Pain 2004; 110: 628–38.
25. D’Urso De Cruz E et al. Long term treatment of DPN and PHN with pregabalin in treatment-resistant patients. ADA 2005.
26. Brasser M, Mallison R, Tilke C. Efficacy and Tolerability of Pregabalin in Patients with Peripheral Neuropathic Pain in Real-Life Settings. EFNS 2006.
27. Graham RG, Hudson DA, Solomons M. A prospective study to assess the outcome of steroid injections and wrist splinting for the treatment of carpal tunnel syndrome. Plast Reconstr Surg 2004; 113 (2): 550–6.
2. Левин О.С. Полинейропатии. М.: МИА, 2005.
3. Johnson EW. Practical Electromyography. Baltimore: Williams and Wilkins, 1980; p. 101, 180, 230.
4. Johnson EW, Kraft GW. Carpal Tunnel Syndrome. Phys Med Rehab Clin N Am 1997; 8: 3.
5. Klippel JH. Primer on the Rheumatic Disease. 12th Ed. Atlanta: Arthritis Foundation, 2001; p. 180.
6. Кипервас И.П. Туннельные синдромы. Изд. 3-е. М.: Ньюдиамед, 2010.
7. Жулев Н.М. Невропатии: руководство для врачей. СПб.: СпБмапо, 2005.
8. Bland JD. Carpal tunnel syndrome. BMJ 2007; 335 (7615): 343–6.
9. Lishman WA, Russel WR. The brachial Neuropathies. Lancet 1961; 2: 941–7.
10. Commesson C et al. Chronic upper extremity pain and co-occurring symptoms in a general population. Arthritis Rheum 2003; 49 (5): 697–702.
11. De Krommc, Kester AD, Knipschild PG et al. Risk factors for carpal tunnel syndrome. Am J Epidemiol 1990; 132 (6): 1102–10.
12. Smith HS, Sang CN. The evolving nature of neuropathic pain: individualizing treatment. Eur J Pain 2002; 6 (Suppl. B): 13–8.
13. Данилов А.Б., Давыдов О.С. Диагностические шкалы для оценки нейропатической боли. Боль. 2007; 3 (16): 11–5.
14. Берзиньш Ю.Э., Думбере Р.Т. Туннельные поражения нервов верхней конечности. Рига: Зинатне, 1989.
15. Данилов А.Б. Габапентин (Нейронтин) в лечении нейропатической боли. Клин. фармакология и терапия. 2004; 13: 4.
16. Wesche D, Bockbrader H. A pharmacokinetic comparison of pregabalin and gabapentin; http://www.ampainsoc.org/abstract/2005/data/684/index.html
17. Levien TL. Summary of new drug applications and biologic license applications submitted to the Food and Drug Administration: Pregabalin-Pfizer. Advances in Pharmacy 2004; 2 (2): 185–6.
18. Taylor CP. The Biology and Pharmacology of Calcium Channel a2-delta Proteins. Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA. CNS Drug Reviews 2003; 10 (2): 183–8.
19. Freynhagen R, Strogek K, GriesingT et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicenter placebo-controlled trial of fexible- and fixed-dose regimen. Pain 2005; 115 (30): 254–63.
20. Siddall PJ, Cousins MJ, Otte A et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67 (10): 1792–800.
21. Vranken JH et al. Pregabalin in patients with central neuropathic pain:
A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2007.
22. Lesser H, Sharma U, La Moreaux L et al. Pregabalin relieves symptoms of painful diabetic europathy randomized control trial. Neurology 2004; 63 (11): 2104–10.
23. Ritcher RW, Portenoy R, Sharma U et al. Relief of painful diabetic neuropathy with pregabalin: a randomized, placebo-controlled trial. Pain 2005; 6 (4): 235–60.
24. Rosenstock J, Truchman M, La Moreaux. Pregabalin feo the gratment of painful diabetic periphera; l neuropathy. A double-blind placebo-controlled trial. Pain 2004; 110: 628–38.
25. D’Urso De Cruz E et al. Long term treatment of DPN and PHN with pregabalin in treatment-resistant patients. ADA 2005.
26. Brasser M, Mallison R, Tilke C. Efficacy and Tolerability of Pregabalin in Patients with Peripheral Neuropathic Pain in Real-Life Settings. EFNS 2006.
27. Graham RG, Hudson DA, Solomons M. A prospective study to assess the outcome of steroid injections and wrist splinting for the treatment of carpal tunnel syndrome. Plast Reconstr Surg 2004; 113 (2): 550–6.
Авторы
Н.В.Пизова, Д.С.Дружинин
ГБОУ ВПО Ярославская государственная медицинская академия Минздрава России
ГБОУ ВПО Ярославская государственная медицинская академия Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.